



# LC-Plasma :

# Driving global expansion through R&D

～Clinical Trials to Support Global Health Claims～

KIRIN R&D DAY 2025


Kirin Holdings Co., Ltd.    Institute of Health Sciences

**Emiri Hiramoto**


# Globalizing LC-Plasma Value Through R&D



## Expanding LC-Plasma into high-growth markets



Regional market size and growth rate of immunity-related products (2022-2027, Billion USD・%)



**Evidence of efficacy that complies with the requirements of relevant national guidelines must be provided**

- Confirmed Effectiveness in Western countries
- Efficacy in Reducing Infectious Disease Symptoms
- Safety Data for Long-Term Consumption

◆ **Currently conducting two clinical trials in Australia**

**Blackmores** : Collaborative Clinical trial

**Griffith University** : Joint Research

◆ **Advancing the understanding of LC-Plasma mechanisms through world-class research**

## ● Outline

Healthy adults  
aged 18–60  
in Australia  
**n=600**

Placebo  
n=300

LC-Plasma  
n=300

0 wk

Intervention

24 wk

LC-Plasma 0 mg/day

LC-Plasma 50 mg/day



Placebo



Active LC-Plasma

Measure symptoms of Upper respiratory tract infection



Blackmores

Product launch expected  
in 2026 or thereafter.

**Strong claims not approved in Japan for social implementation.**

## ● Outline

Healthy adults  
aged 18–60  
in Australia  
**n=220**

Placebo  
n=110

LC-Plasma  
n=110

-4 wk Pre-observation 0 wk Intervention 4 wk

LC-Plasma 0 mg/day

LC-Plasma 50 mg/day



Placebo



Active  
LC-Plasma

- Measure symptoms of Upper respiratory tract infection
- Antigen detection of Influenza A/B, RSV, and Coronavirus
- Immune markers including pDC activity (broadly assessed by CyTOF to identify novel markers)

Obtaining new health  
claims globally

Increasing the global value of LC-Plasma  
by advancing its mechanistic insights

Publication expected in Q4 2026

## CyTOF (Cytometry by Time-Of-Flight)

### Cutting-edge analytical technology to clarify the mechanism of action

(widely utilized in vaccine development and other advanced applications)

Using metal-tagged antibodies, CyTOF enables simultaneous measurement of over 40 protein markers at single-cell resolution, providing a comprehensive and detailed profile of each cell.

Decoding immune system dynamics to **elevate LC-Plasma research to a world-class scientific standard**

## Academia

- Unveiling the effectiveness of LC-Plasma against the Southeast Asian threat of “dengue fever”, in collaboration with world-renowned infectious disease expert Prof. Abu Bakar of University of Malaya
- Partnering with Prof. Suresh of Griffith University as a KOL

**Strategic alliances with immunology experts  
to drive global growth of LC-Plasma**